ID   T47D-LTED
AC   CVCL_YX85
SY   T47D LTED; T47D-Long Term Estrogen-Deprived
DR   Wikidata; Q98133073
RX   PubMed=26116361;
CC   Characteristics: Derived from parental cell line by long-term culture in the presence of RPMI-1640 medium containing 10% dextran charcoal stripped serum (DCC).
CC   Sequence variation: Heterozygous for PIK3CA p.His1047Arg (c.3140A>G) (ClinVar=VCV000013652) (from parent cell line).
CC   Sequence variation: Homozygous for TP53 p.Leu194Phe (c.580C>T) (ClinVar=VCV000127817) (from parent cell line).
CC   Derived from metastatic site: Pleural effusion.
DI   NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0553 ! T-47D
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 12-03-20; Last updated: 29-10-20; Version: 3
//
RX   PubMed=26116361; DOI=10.1158/1535-7163.MCT-15-0143;
RA   Ribas R., Pancholi S., Guest S.K., Marangoni E., Gao Q., Thuleau A.,
RA   Simigdala N., Polanska U.M., Campbell H., Rani A., Liccardi G.,
RA   Johnston S.R.D., Davies B.R., Dowsett M., Martin L.-A.;
RT   "AKT antagonist AZD5363 influences estrogen receptor function in
RT   endocrine-resistant breast cancer and synergizes with fulvestrant
RT   (ICI182780) in vivo.";
RL   Mol. Cancer Ther. 14:2035-2048(2015).
//